Currently,the available antiparasitic drugs for toxoplasmosis include sulfonamides(e.g., sulfadiazine), DHFR inhibitors (pyrimethamine, trimethoprim),and the naphthoquinone atovaquone. However,adverse effects such as nephrotoxicity, alongside the emergence of drug-resistant clinical isolates, highlightthe urgent need for novel and effective therapeutic agents for thetreatment and management of toxoplasmosis. The gene discussed is DHFR; the disease is toxoplasmosis.